Investigation of Gastric Motility in Patients With the Overlap Syndrome of the Gastroesophageal Reflux Disease and Functional Dyspepsia

Пасечников, В. Д.; Голубь, И. В.

doi:10.18786/2072-0505-2017-45-5-377-383

Cited by 5 publications

(5 citation statements)

References 23 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Given the fact that PPIs are an over-the-counter medication [ 46 ], they are easily prescribed and dispensed, commonly used and very well marketed, especially in the US. Analyses from the database showed that 12.5% of the US population recruited over the last 20 years were on PPIs.…”

Section: Discussionmentioning

confidence: 99%

Cirrhotic patients on proton pump inhibitors are at a twofold risk of spontaneous bacterial peritonitis independently of gastrointestinal bleeding: a population-based retrospective study

Boustany

Rahhal

Onwuzo

et al. 2023

aog

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Cirrhotic patients on proton pump inhibitors are at a twofold risk of spontaneous bacterial peritonitis independently of gastrointestinal bleeding: a population-based retrospective study

Boustany

Rahhal

Onwuzo

et al. 2023

aog

View full text Add to dashboard Cite

“…PPIs are considered the first line of treatment for GERD, but many studies have reported that some patients with mucosal injury of the esophagus do not respond and that many patients with GERD are resistant to or only partially respond to PPI treatment. Therefore, recent trials compared 20 mg of vonoprazan once daily to PPIs in terms of effectiveness, safety, and side effects and reported improved vonoprazan response [ 35 ]. Similarly, this study also showed that vonoprazan is effective and tolerable for treatment in terms of reducing the burden of H. pylori infection and reducing the symptoms of GERD [ 36 ].…”

Section: Discussionmentioning

confidence: 99%

“…According to one study, people with PPI-resistant GERD who switched to vonoprazan medication showed an improvement in GERD symptoms in addition to fewer side effects. Eighteen patients (69.2%) reported improved symptoms following the switch from PPI to vonoprazan medication, whereas six (23.1%) showed no change and two (7.7%) had worsening symptoms [ 35 ]. These findings are comparable with the findings of the present study, which stated that 1570 (96.9%) patients had overall symptoms that improved, whereas 45 patients (2.8%) had no change, and five (0.3%) had symptoms that got worse after the use of vonoprazan treatment.…”

Section: Discussionmentioning

confidence: 99%

Real-World Evidence to Evaluate the Efficacy and Safety of Vonoprazan in Gastrointestinal Disorders in the Pakistani Population

Abbasi,

Siddiqui,

Ram

et al. 2023

Cureus

View full text Add to dashboard Cite

Background and aim: While proton pump inhibitor (PPI) therapy has proven to be effective in managing gastroesophageal reflux disease (GERD), a notable portion of patients who experience GERD symptoms may not respond to this treatment. Research suggests that roughly 30% of individuals with a presumed GERD diagnosis may continue to experience symptoms, whether partially or completely, even when receiving PPI therapy. The aim of this study was to assess the treatment of gastrointestinal diseases with a novel potassium-competitive acid blocker (P-CAB), vonoprazan, in terms of its effectiveness and safety in the Pakistani population. Methods: This prospective, multicenter, observational study was conducted in Pakistan. This study included 1,642 patients from January 2023 to August 2023, aged 18 years, with gastrointestinal disorders. All demographic data, medical history, GERD severity assessment questionnaire (GerdQ), and laboratory parameters, including stool assessment for Helicobacter pylori (H. pylori), were observed. Patients were orally treated with vonoprazan at doses of 10 mg or 20 mg, once or twice daily. Statistical analysis was done by one-way ANOVA. Results: Out of 1,642 patients, 840 (51.2%) were males and 802 (48.8%) were females, with a mean age of 39.81±14.61 years. The mean GerdQ score at baseline was 20.37±15.87, 7.24±8.15 at the second week of treatment, and 3.70±6.31 at the fourth week of treatment (p<0.001). 90.74% of patients achieved H. pylori eradication. Most patients were acid regurgitation and heartburn-free for >70% of days. Most of the patients, 1,283 (78.13%), exhibited good treatment compliance. Mild adverse events were reported in 37 (2.3%) patients. Conclusions: The use of vonoprazan significantly reduced the likelihood of GERD by improving symptoms and was also highly effective in the elimination of H. pylori infections. Vonoprazan was generally well tolerated.

show abstract

“…Нарушение аккомодация желудка выявлено у 40% пациентов с синдромом перекреста ГЭРБ и функциональной диспепсии (аккомодационный рефлекс развивался с задержкой от 5 до 25 минут), у остальных 60% он оказался достоверно сниженным по сравнению со здоровыми людьми. При этом достоверно большая выраженность симптомов наблюдалась у больных, имеющих расстройства аккомодации желудка [66].…”

Section: гастроэзофагеальная рефлюксная болезньunclassified

Gastric accommodation: pathogenetic role and clinical significance

Shklyaev

2024

ECG

View full text Add to dashboard Cite

The article presents a literature review of modern Russian and foreign publications devoted to the study of gastric accommodation. It has been shown that accommodation of the proximal stomach plays an important role in its adaptation to food intake. This process is carried out in two stages with the participation of parasympathetic and paracrine regulation; the effects of nutrients when they enter the duodenum also play an important role. Methods for assessing gastric accommodation include gastric barostat, gastric scintigraphy with food load, drinking tests, single-photon emission computed tomography, magnetic resonance imaging and ultrasound examination of the stomach, intragastric manometry. Violation of gastric accommodation leads to an excessive increase in intragastric pressure and the occurrence of symptoms most often found in functional dyspepsia, gastroesophageal reflux disease and diabetic gastropathy. Approaches to the treatment of gastric accommodation disorders are at the development stage, the possibilities of diet therapy, pharmacological and non-drug correction are being discussed.

show abstract

Investigation of Gastric Motility in Patients With the Overlap Syndrome of the Gastroesophageal Reflux Disease and Functional Dyspepsia

Cited by 5 publications

References 23 publications

Cirrhotic patients on proton pump inhibitors are at a twofold risk of spontaneous bacterial peritonitis independently of gastrointestinal bleeding: a population-based retrospective study

Cirrhotic patients on proton pump inhibitors are at a twofold risk of spontaneous bacterial peritonitis independently of gastrointestinal bleeding: a population-based retrospective study

Real-World Evidence to Evaluate the Efficacy and Safety of Vonoprazan in Gastrointestinal Disorders in the Pakistani Population

Gastric accommodation: pathogenetic role and clinical significance

Contact Info

Product

Resources

About